Private Prescription Access to Both Weight Management Options
Why Switch From Wegovy to Mounjaro Through Private Prescription
Patients considering switching from Wegovy to Mounjaro often face lengthy NHS processes involving GP referrals and specialist appointments. Private prescription services eliminate these barriers, offering direct access to clinical assessment for both semaglutide (Wegovy) and tirzepatide (Mounjaro) medications. The key difference lies in their mechanisms: Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 pathways as a dual agonist. This distinction may explain why some patients respond differently to each treatment option.
EverydayMeds streamlines the switch from Wegovy to Mounjaro process through our comprehensive clinical assessment platform. Our prescribers evaluate your current treatment response, side effect profile, and medical history to determine the most appropriate prescription-only medicine for your circumstances. Unlike NHS pathways requiring months of waiting, private prescription assessment typically completes within 24-72 hours, enabling seamless transition between weight management medications without treatment interruption.
Wegovy and Mounjaro Pricing Structure for Private Patients
When planning your switch from Wegovy to Mounjaro, understanding the cost implications helps inform your decision. Wegovy pricing through EverydayMeds starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout to reach these final prices, whilst returning customers use DOSE25 for their discount allocation.
Mounjaro pricing follows a similar escalation pattern, though costs vary between the two medications based on manufacturing and supply factors. Bundle options provide convenience for patients requiring multiple pens, such as our Intro Trio (0.25mg, 0.5mg, 1mg) at £299.99 or Ultimate Stability Trio (three 2.4mg pens) for £649.99. These bundles ensure treatment continuity during your switch from Wegovy to Mounjaro transition period, eliminating the need for multiple separate orders.
Clinical Evidence Supporting Wegovy to Mounjaro Transition Decisions
The STEP trial programme demonstrated Wegovy's efficacy, with participants achieving approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). Patients experienced sustained weight management benefits, though individual responses varied considerably across the study population. These results established semaglutide as an effective prescription-only medicine for eligible adults with elevated BMI.
Mounjaro's clinical development through the SURMOUNT trials revealed different response patterns, potentially explaining why some patients consider switching from Wegovy to Mounjaro. The dual GIP/GLP-1 mechanism may offer advantages for specific patient populations, though direct head-to-head comparisons remain limited due to different trial designs and endpoints. Both medications require administration alongside reduced-calorie diet and increased physical activity for optimal effectiveness.
Understanding Wegovy's Mechanism Before Switching
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and glucose metabolism. The medication binds to GLP-1 receptors in the brain's appetite centres, promoting satiety signals that reduce food intake and cravings. This mechanism slows gastric emptying, prolonging feelings of fullness after meals and naturally supporting portion control efforts. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system provides consistent medication levels throughout the treatment period. Patients typically notice appetite changes within the first few weeks of treatment, though optimal weight management results develop over several months of consistent use.
Streamlined Ordering Process for Medication Transitions
Switching from Wegovy to Mounjaro through EverydayMeds begins with our comprehensive three-minute clinical assessment, covering your current treatment history, response patterns, and medical background. Our prescribers review applications within standard timeframes (72 hours) or express service (24 hours) for urgent requirements, ensuring minimal treatment gaps during medication transitions. Once approved, both Wegovy and Mounjaro ship via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. The GPhC-registered pharmacy (#9012878) ensures authentic medication supply directly from licensed wholesalers, eliminating counterfeit product risks associated with unregulated suppliers. Payment processing includes automatic discount code application at checkout, providing transparent pricing without hidden fees.
Storage and Practical Considerations for Medication Switching
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, though their room temperature stability differs significantly. Wegovy maintains potency for up to six weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This storage advantage may influence travel plans and lifestyle compatibility when considering your switch from Wegovy to Mounjaro options. The FlexTouch pen delivery system remains consistent between both medications, minimising learning curves for injection technique and dose administration. Dose escalation schedules follow similar patterns, starting with lower doses and gradually increasing to therapeutic levels over 16-20 week periods.
Private Prescription Advantages for Wegovy-Mounjaro Switching
NHS medication switching typically requires specialist referral, appointment scheduling, and formulary approval processes that can delay treatment transitions by several months. Private prescription services bypass these administrative hurdles, enabling immediate clinical assessment for alternative weight management medications. Prescribers can evaluate your Wegovy response profile and determine Mounjaro suitability without requiring GP involvement or specialist weight management service referrals.
The flexibility of private prescription allows for personalised treatment approaches that may not align with NHS commissioning guidelines or local formulary restrictions. Patients can access both medications simultaneously during transition periods, ensuring treatment continuity whilst minimising withdrawal effects or appetite rebound. This approach proves particularly valuable for individuals with specific medical conditions, medication sensitivities, or lifestyle requirements that standard NHS pathways struggle to accommodate.
Complete Your Switch From Wegovy to Mounjaro Today
Ready to explore your medication options without NHS delays? EverydayMeds provides immediate access to clinical assessment for both Wegovy and Mounjaro through our streamlined private prescription service. Our expert prescribers evaluate your individual circumstances to determine the most appropriate treatment pathway, whether continuing Wegovy or transitioning to Mounjaro's dual-action formula. New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 for their discount allocation. Complete your assessment at https://everydaymeds.co.uk/collections/wegovy and receive next-day delivery once approved. Treatment decisions should always involve qualified healthcare professionals who can assess your specific medical history and weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
